Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best ...

South Africa has made history by becoming the first African nation to register Lenacapavir, a revolutionary long-acting ...

SAHPRA chief executive Dr Boitumelo Semete-Makokotlela said the product is “the most effective HIV prevention measure thus ...

The timing of the renewed support is pivotal. South Africa is preparing to roll out Lenacapavir, a groundbreaking long-acting ...

By William Baloyi When President Donald Trump issued an executive order suspending all foreign aid to South Africa, in ...

KZN to receive Lenacapavir,new long-acting HIV prevention injection. Minister Motsoaledi confirms rollout to 360 clinics, for 6-month protection dose ...

Dr Joel Steingo of TB HIV Care says Lenacapavir could be a breakthrough in reducing infections, especially at a time when ...

HIV prevention drug Lenacapavir, which has been tested in South Africa during clinical trials, will be made available in the country in 2026 for high-risk groups.

Camber Pharmaceuticals’ parent company, Hetero, a global company specializing in active pharmaceutical ingredients and ...

SAHPRA has registered Lenacapavir, a new six-monthly PrEP injection to prevent HIV-1 in adults and adolescents over 35 kg.